Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study
Anti-CD20 therapies appear to be a safe option after NTZ discontinuation, with no rebound disease and stable EDSS. PIRA was the main driver for disability progression, emphasizing the need to control smoldering disease.
Authors
- Inês Carvalho (ORCID: https://orcid.org/0000-0003-2523-4754)
- Inês Correia (ORCID: https://orcid.org/0000-0003-1863-9489)
- Lívia Sousa (ORCID: https://orcid.org/0000-0002-7463-3578)
- Sónia Batista (ORCID: https://orcid.org/0000-0002-6081-6955)
- Carolina Cunha (ORCID: https://orcid.org/0000-0002-0639-4990)
- Isabel Campelo
- João Cardoso (ORCID: https://orcid.org/0000-0003-0255-1714)
- Carmo Macário (ORCID: https://orcid.org/0000-0002-8267-2673)
- Carla Nunes (ORCID: https://orcid.org/0000-0001-5717-3437)
- Catarina Bernardes (ORCID: https://orcid.org/0009-0003-7322-2800)
- Sara Matos
Institutions
- Hospitais da Universidade de Coimbra (PT)
- University of Coimbra (PT)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.msard.2025.106564
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09